Skip to main content
. Author manuscript; available in PMC: 2023 Jan 4.
Published in final edited form as: Annu Rev Biomed Eng. 2022 Apr 6;24:275–305. doi: 10.1146/annurev-bioeng-110320-110749

Table 1.

Ongoing and completed clinical trials of drugs directly targeting immune cell recruitment to tumors

Clinical trial identifier Immune cell type Purpose of study
NCT02179970 T cells and NK cells Safety of continuous intravenous administration of plerixafor in patients with advanced pancreatic, ovarian, and colorectal cancers
NCT04523662 Multiple immune cell types Effectiveness and safety of camrelizumab combined with apatinib mesylate and radiotherapy in the treatment of advanced liver cancer
NCT02650427 T cells and NK cells Safety of a 3-week sitagliptin treatment in HCC patients undergoing liver resection
NCT03896113 T cells Neoadjuvant celecoxib in newly diagnosed patients with endometrial carcinoma
NCT04798612 T cells Effect of low-dose interferon-α2a on perioperative immune suppression

Abbreviations: HCC, hepatocellular carcinoma; NK, natural killer.